ANIP vs EMBC: fair value comparison
ANI Pharmaceuticals, Inc. and Embecta Corp. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EMBC currently sits closer to the top of our discount ranking. EMBC carries the stronger momentum grade.
| ANIP | EMBC | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $80.06 | $3.72 |
| 12-month range | $75.22–$94.10 | $3.29–$14.27 |
| Sector rank | #11 of 113 Healthcare | #3 of 113 Healthcare |
| Quality grade | C- | C- |
| Momentum grade | B | A |
| Leverage | Moderate | Low |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: ANIP fair value analysis · EMBC fair value analysis